发布求助
文献互助 智能选刊 最新文献

Mental Health Clinician最新文献

筛选
英文 中文
Clozapine clinical toolkit optimizes inpatient clozapine monitoring 氯氮平临床工具包可优化住院患者氯氮平监测
Mental Health Clinician Pub Date : 2024-04-01 DOI: 10.9740/mhc.2024.04.085
Brooke Gessner, Michelle Carter, Alberto Almeida, Colleen Borralho, Kiana Rahnama, Tamara Mihic, Joan C. Y. Ng, J. Puyat, A. Russolillo, Katelyn Halpape
{"title":"Clozapine clinical toolkit optimizes inpatient clozapine monitoring","authors":"Brooke Gessner, Michelle Carter, Alberto Almeida, Colleen Borralho, Kiana Rahnama, Tamara Mihic, Joan C. Y. Ng, J. Puyat, A. Russolillo, Katelyn Halpape","doi":"10.9740/mhc.2024.04.085","DOIUrl":"https://doi.org/10.9740/mhc.2024.04.085","url":null,"abstract":"\u0000 \u0000 \u0000 Clozapine is the most effective antipsychotic in the management of treatment-resistant schizophrenia; however, its use is challenging due to the risk of severe adverse effects. Despite the risks associated with clozapine, there is no mandatory monitoring in Canada beyond hematologic testing for agranulocytosis surveillance. This study focuses on the development, implementation, and evaluation of a clozapine clinical toolkit (CTK) targeted at optimizing inpatient clozapine use.\u0000 \u0000 \u0000 \u0000 A comprehensive literature review was conducted to identify clozapine best practices, experts were consulted, and a comprehensive clozapine CTK was developed and implemented at a large Canadian tertiary hospital in December 2018. To evaluate the CTK, a retrospective chart review was conducted to assess for change in guideline-concordant monitoring pre- and post- CTK implementation. Patients were included if they were > 18 years of age and received clozapine during inpatient admission. Results were analyzed using descriptive and inferential statistics.\u0000 \u0000 \u0000 \u0000 Among the charts reviewed, 185 and 113 admissions met the pre- and post-CTK inclusion criteria, respectively. Staff used the CTK in the care of 96% of clozapine patients post implementation, and its use resulted in improvements in guideline-concordant monitoring for agranulocytosis and myocarditis.\u0000 \u0000 \u0000 \u0000 Implementation of the clozapine CTK increased the concordance of clozapine monitoring with best practice recommendations. Future research is necessary to assess the impact of the CTK on clinical outcomes and patient satisfaction.\u0000","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"76 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140794325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Training student pharmacists to administer long-acting injectable medications 培训学生药剂师管理长效注射药物
Mental Health Clinician Pub Date : 2024-04-01 DOI: 10.9740/mhc.2024.04.107
M. Ehret, Raymond C. Love, Bethany DiPaula
{"title":"Training student pharmacists to administer long-acting injectable medications","authors":"M. Ehret, Raymond C. Love, Bethany DiPaula","doi":"10.9740/mhc.2024.04.107","DOIUrl":"https://doi.org/10.9740/mhc.2024.04.107","url":null,"abstract":"\u0000 \u0000 \u0000 In June of 2022, the State of Maryland Board of Pharmacy issued regulations permitting pharmacist administration of maintenance injectable medications. Subsequently, the University of Maryland School of Pharmacy created a laboratory to train student pharmacists based on these regulations on administering long-acting maintenance injections. This training included a review of regulations, reconstitution and administration of medications, and education for patients and caregivers on long-acting injectable medications. This is the first training the authors are aware of incorporating both reconstitution and administration of these medications. The objective of this paper is to describe the laboratory details and future directions of the training course.\u0000 \u0000 \u0000 \u0000 The first training laboratory trained 94 student pharmacists in the administration technique of long-acting injectable medications. The program has been adapted for practicing pharmacists and other healthcare providers. Thus far, more than 300 practitioners have participated in the learning lab.\u0000","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"168 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AAPP 2024 Annual Meeting Poster Abstracts 亚洲政党年会 2024 年会海报摘要
Mental Health Clinician Pub Date : 2024-04-01 DOI: 10.9740/mhc.2024.04.111
{"title":"AAPP 2024 Annual Meeting Poster Abstracts","authors":"","doi":"10.9740/mhc.2024.04.111","DOIUrl":"https://doi.org/10.9740/mhc.2024.04.111","url":null,"abstract":"","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"50 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140791765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacologic treatment of bipolar disorder and comorbid adult attention-deficit/hyperactivity disorder 双相情感障碍和合并成人注意缺陷/多动障碍的药物治疗
Mental Health Clinician Pub Date : 2024-04-01 DOI: 10.9740/mhc.2024.04.082
Anuja Vallabh
{"title":"Pharmacologic treatment of bipolar disorder and comorbid adult attention-deficit/hyperactivity disorder","authors":"Anuja Vallabh","doi":"10.9740/mhc.2024.04.082","DOIUrl":"https://doi.org/10.9740/mhc.2024.04.082","url":null,"abstract":"","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"431 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140776170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Off-label use of duloxetine for pediatric neuropathic pain 度洛西汀治疗小儿神经性疼痛的说明书外用药
Mental Health Clinician Pub Date : 2015-11-19 DOI: 10.9740/MHC.2015.11.277
K. Burghardt, S. Thomas, V. Tutag-Lehr
{"title":"Off-label use of duloxetine for pediatric neuropathic pain","authors":"K. Burghardt, S. Thomas, V. Tutag-Lehr","doi":"10.9740/MHC.2015.11.277","DOIUrl":"https://doi.org/10.9740/MHC.2015.11.277","url":null,"abstract":"Abstract Introduction: Duloxetine, a serotonin-norepinephrine reuptake inhibitor, has been used successfully for adults for the management of neuropathic pain syndromes. Pediatric data are needed because inadequate neuropathic pain management in children and adolescents results in lower psychosocial functioning, delayed development, and decreased quality of life. We aim to describe a case series on the use of duloxetine for the management of symptoms associated with chronic neuropathic pain syndromes in a pediatric population. Methods: Data were collected in a naturalistic, consecutive, case report format, from a pediatric pain management clinic for children prescribed duloxetine for analgesia for a variety of neuropathic-type pain conditions. Follow-up data, including self-report of pain, and type and frequency of adverse reactions, were collected to describe the efficacy and safety of duloxetine. Results: Duloxetine was prescribed for the management of self-reported average pain scores of greater than 5...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"40 1","pages":"277-283"},"PeriodicalIF":0.0,"publicationDate":"2015-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82820944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacologic basis for the use of selective norepinephrine reuptake inhibitors for the treatment of neuropathic pain conditions 选择性去甲肾上腺素再摄取抑制剂治疗神经性疼痛的药理学基础
Mental Health Clinician Pub Date : 2015-11-19 DOI: 10.9740/MHC.2015.11.284
M. Webster
{"title":"Pharmacologic basis for the use of selective norepinephrine reuptake inhibitors for the treatment of neuropathic pain conditions","authors":"M. Webster","doi":"10.9740/MHC.2015.11.284","DOIUrl":"https://doi.org/10.9740/MHC.2015.11.284","url":null,"abstract":"Abstract Introduction: This article will review the pharmacologic and clinical evidence supporting the use of selective norepinephrine reuptake inhibitors, most notably atomoxetine, for the treatment of neuropathic pain states. Many medications initially marketed for psychiatric indications have gained widespread use for their analgesic properties after additional research. Methods: In search of alternative treatments for neuropathic pain, current guidelines, published reviews, and primary literature, including both rodent and human trials, were reviewed. Results and Discussion: The first group of medications to gain widespread use in pain management was the tricyclic antidepressants. As further research was completed and serotonin norepinephrine reuptake inhibitors began to be utilized for their analgesic properties, a growing body of evidence began to indicate that the analgesic properties of these medications were primarily due to the blockade of norepinephrine reuptake with serotonin playing only a mi...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"12 1","pages":"284-288"},"PeriodicalIF":0.0,"publicationDate":"2015-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87600821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors for menopausal vasomotor symptoms 选择性血清素再摄取抑制剂和血清素去甲肾上腺素再摄取抑制剂治疗绝经期血管舒缩症状
Mental Health Clinician Pub Date : 2015-11-19 DOI: 10.9740/MHC.2015.11.260
K. Holt, A. Thompson
{"title":"Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors for menopausal vasomotor symptoms","authors":"K. Holt, A. Thompson","doi":"10.9740/MHC.2015.11.260","DOIUrl":"https://doi.org/10.9740/MHC.2015.11.260","url":null,"abstract":"Abstract Introduction: Some of the most bothersome symptoms associated with menopause are the vasomotor symptoms (VMS), characterized by transient elevations in body temperature associated with a narrowing of the thermoneutral zone and an abnormal firing rate of thermosensitive neurons in the hypothalamus. These VMS have traditionally been treated with hormone replacement therapy (HRT); however, after a trial suggesting an association between HRT and a number of serious adverse events, alternative therapies for VMS are being studied. The purpose of this review is to evaluate the available literature regarding the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) for the alleviation of VMS associated with menopause. Methods: PubMed and Ovid/MEDLINE keyword searches were conducted. Literature was reviewed for inclusion if it included any SSRI or SNRI for menopausal symptoms published prior to August 31, 2014. Results: Seven studies were included ...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"135 1","pages":"260-264"},"PeriodicalIF":0.0,"publicationDate":"2015-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87912506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triiodothyronine (T3) supplementation in major depressive disorder 补充三碘甲状腺原氨酸(T3)治疗重度抑郁症
Mental Health Clinician Pub Date : 2015-11-19 DOI: 10.9740/MHC.2015.11.253
Anna K. Morin
{"title":"Triiodothyronine (T3) supplementation in major depressive disorder","authors":"Anna K. Morin","doi":"10.9740/MHC.2015.11.253","DOIUrl":"https://doi.org/10.9740/MHC.2015.11.253","url":null,"abstract":"Abstract Introduction: The use of thyroid hormones to enhance the effects of antidepressants is based on evidence supporting a link between thyroid function and Major Depressive Disorder. Thyroid abnormalities have been found in patients with Major Depressive Disorder and have been correlated with depression severity. Symptoms associated with clinical hypothyroidism include mood disturbances, primarily depression. In addition, an increase in antidepressant treatment resistance has been associated with thyroid abnormalities. This article reviews the existing data regarding triiodothyronine (T3) supplementation of antidepressants in the treatment of major depressive disorder. Methods: Medline and EMBASE were searched from 1996 to November 2014 using the key terms triiodothyronine, T3, and treatment-resistant depression. Results: T3 may increase serotonergic neurotransmission and has been studied as an add-on agent in patients with unipolar depression with and without thyroid dysfunction to accelerate, enhan...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"42 1","pages":"253-259"},"PeriodicalIF":0.0,"publicationDate":"2015-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91198055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors for the treatment of painful neuropathy 使用血清素和去甲肾上腺素再摄取抑制剂治疗疼痛性神经病变的证据和临床考虑
Mental Health Clinician Pub Date : 2015-11-19 DOI: 10.9740/MHC.2015.11.289
M. Sigler, A. Vandenberg, A. Thompson
{"title":"Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors for the treatment of painful neuropathy","authors":"M. Sigler, A. Vandenberg, A. Thompson","doi":"10.9740/MHC.2015.11.289","DOIUrl":"https://doi.org/10.9740/MHC.2015.11.289","url":null,"abstract":"Abstract Introduction: Peripheral neuropathy is a painful condition that can lead to a reduction in quality of life. The pain, which stems from damaged, hyperexcitable neurons, does not respond to traditional analgesics. However, due to the underlying mechanism of pain, some antidepressants are effective in managing peripheral neuropathy. The purpose of this review is to evaluate the available literature on serotonin-norepinephrine reuptake inhibitors for the management of peripheral neuropathy and outline clinical considerations for choosing an agent. Methods: PubMed, Ovid/MEDLINE, and Scopus queries were conducted for relevant literature. Search types were limited to keyword searches and articles were limited to those published prior to March 31, 2015. Results: There were 19 randomized controlled trials included in this review. No articles were found investigating the use of desvenlafaxine, milnacipran, or levomilnacipran for treatment of neuropathy. Both duloxetine and venlafaxine improved pain severit...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"18 1","pages":"289-295"},"PeriodicalIF":0.0,"publicationDate":"2015-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73012754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Off-label use of mirtazapine for anxiety 使用米氮平治疗焦虑
Mental Health Clinician Pub Date : 2015-11-19 DOI: 10.9740/MHC.2015.11.265
J. Begert, Bridget Bradley
{"title":"Off-label use of mirtazapine for anxiety","authors":"J. Begert, Bridget Bradley","doi":"10.9740/MHC.2015.11.265","DOIUrl":"https://doi.org/10.9740/MHC.2015.11.265","url":null,"abstract":"Abstract Introduction: Currently, mirtazapine is only approved for use in patients with major depressive disorder, yet the unique dual mechanism of action for this agent has led many to inquire about potential alternative uses. The purpose of this article is to review the evidence available and evaluate the efficacy and tolerability of mirtazapine for use in patients presenting with various forms of anxiety. Methods: A search of the medical literature using Ovid Medline and the search terms “mirtazapine” and “anxiety disorders” resulted in the identification of 12 trials and 1 meta-analysis investigating off-label mirtazapine use in various subsets of anxiety. Results: Upon review of the literature, mirtazapine was found to perform significantly better than placebo at controlling symptoms of anxiety with comorbid depression, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder; and with comparable efficacy, in some cases with significantly better respon...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"11 1","pages":"265-270"},"PeriodicalIF":0.0,"publicationDate":"2015-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79641385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信